This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness

This study has been completed.
Information provided by:
Sociedad Española de Neumología y Cirugía Torácica Identifier:
First received: August 4, 2005
Last updated: April 2, 2007
Last verified: April 2006

The objective of the study is to evaluate the effect of CPAP over the incidence of cardiovascular events and diagnosis of arterial hypertension in patients with sleep apnea.

The hypothesis of the study is the following: The existence of sleep disordered breathing in the general population is associated to an increased incidence of arterial hypertension and to an increased risk of suffering cardiovascular disease. CPAP corrects respiratory disorders during sleep. Treatment with CPAP in subjects with sleep disordered breathing without daytime sleepiness reduces the incidence of systemic arterial hypertension and cardiovascular complications.

The end points of the study are new diagnosis of arterial hypertension and new cardiovascular events.

All patients, after randomization, will be followed for three years.

Condition Intervention Phase
Sleep Apnea Hypertension Cardiovascular Diseases Device: CPAP (Continuous Positive Airway Pressure) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness

Resource links provided by NLM:

Further study details as provided by Sociedad Española de Neumología y Cirugía Torácica:

Primary Outcome Measures:
  • Incidence of hypertension
  • Incidence of cardiovascular events

Secondary Outcome Measures:
  • Relationship between hypertension and sleep apnea/hypopnea syndrome (SAHS) severity
  • Relationship between cardiovascular events and SAHS severity

Estimated Enrollment: 700
Study Start Date: May 2004
Estimated Study Completion Date: April 2006

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Epworth <10
  • Apnea-Hypopnea Index ≥20

Exclusion Criteria:

  • Presence of any chronic disease
  • Presence of cardiovascular disease
  • Refusal to sign informed consent
  • Drug addiction and/or alcoholism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00127348

Hospital Univ Arnau de Vilanova
Lleida, Catalonia, Spain, 25198
Sponsors and Collaborators
Sociedad Española de Neumología y Cirugía Torácica
Principal Investigator: Ferran Barbe, MD Hospital Universitari Arnau de Vilanova. Lleida. Spain
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00127348     History of Changes
Other Study ID Numbers: PI 040165
Study First Received: August 4, 2005
Last Updated: April 2, 2007

Additional relevant MeSH terms:
Cardiovascular Diseases
Sleep Apnea Syndromes
Vascular Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases processed this record on September 21, 2017